Terug

Koninklijke DSM N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 11 feb 2015 - 07:15
  • Statutaire naam Koninklijke DSM N.V.
  • Titel DSM reports 2014 results
  • Bericht • 2014 sales of €9,181 million • Organic sales growth 5% in Q4 2014 and 3% for 2014 • Q4 2014 EBITDA €288 million and 2014 EBITDA €1,168 million • Strong cash from operating activities of €418 million in Q4 2014 (€808 million in 2014) • Non-cash impairment of €186 million of the caprolactam business (after tax and non-controlling interests) included in exceptional items, leading to a net loss in Q4 2014 • Proposed dividend stable at €1.65 per ordinary share • DSM will take further actions to improve efficiencies and to reduce costs • DSM aims to deliver 2015 EBITDA slightly ahead of 2014

Gerelateerde downloads

201502110000000006_DSM_Presentation to Investors PDF.pdf
201502110000000006_DSM_Press release-PDF.pdf

Datum laatste update: 27 oktober 2021

Informatie delen

Delen via: deel